Verzenio (abemaciclib) - Eli Lilly
Verzenio: "Abemaciclib + NSAI and Abemaciclib + fulvestrant showed significant PFS benefit in predominantly Chinese HR +/HER –advanced breast cancer patients"; Breast cancer (Eli Lilly) - Oct 3, 2019 - ESMO 2019 
P3 data
https://edge.media-server.com/mmc/p/r97hwdre
 
Oct 3, 2019
 
 
9f810381-0821-42fb-a982-d4ddb8a1e35a.jpg

d26c3c3a-3138-4699-a6da-b8bd26bfed7a.jpg